Mechanism of Yangxinshi Intervention on Cardiac Fibrosis in Diabetic Cardiomyopathy Based on Network Pharmacology
Background. Cardiac fibrosis (CF) is major myocardial change in diabetic cardiomyopathy (DCM). Yangxinshi as a Chinese medicine formula is used to treat cardiovascular diseases. However, the exact effective mechanism of Yangxinshi on CF is still uncertain. Hence, based on the pharmacological network, predicting the active components, potential targets and pathways of Yangxinshi on diabetic fibrosis require to be further studied. Materials and Methods. By using Cytoscape 3.6.0 Bisogenet plug-in, the active components of Yangxinshi were obtained and screened through TCMSP, and the PPI network of DCM-CF was constructed and then screened by CytoNCA plug-in. GO analysis and KEGG pathway enrichment analysis were carried out by Cluego plug-in. Combined with the results of network pharmacological analysis, cells in vitro were performed to verify the CF stimulated with high glucose or intervence with Yangxinshi, and the expressions of Cbl-b, p-smad2, and α-SMA were detected. Results. Yangxinshi might play a key role in reversing cardiac fibrosis in individuals with DCM by regulating the signal pathway of CBL and promoted the expression of Cbl-b and inhibited the expression of p-smad2 and α-SMA, verifying some predictive work via network pharmacology. Conclusion. Based on network pharmacology, this study demonstrates that the beneficial effect of Yangxinshi on CF is related to the Cbl-b/smad2 pathway, providing an idea for the therapeutic effect of Yangxinshi on cardiac fibrosis in DCM..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Evidence-Based Complementary and Alternative Medicine - (2022) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiangying Kuang [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1155/2022/3968494 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ061187887 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ061187887 | ||
| 003 | DE-627 | ||
| 005 | 20230501190546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1155/2022/3968494 |2 doi | |
| 035 | |a (DE-627)DOAJ061187887 | ||
| 035 | |a (DE-599)DOAJ87aff6f4dca747af80123bfe82779e13 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RZ201-999 | |
| 100 | 0 | |a Jiangying Kuang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mechanism of Yangxinshi Intervention on Cardiac Fibrosis in Diabetic Cardiomyopathy Based on Network Pharmacology |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background. Cardiac fibrosis (CF) is major myocardial change in diabetic cardiomyopathy (DCM). Yangxinshi as a Chinese medicine formula is used to treat cardiovascular diseases. However, the exact effective mechanism of Yangxinshi on CF is still uncertain. Hence, based on the pharmacological network, predicting the active components, potential targets and pathways of Yangxinshi on diabetic fibrosis require to be further studied. Materials and Methods. By using Cytoscape 3.6.0 Bisogenet plug-in, the active components of Yangxinshi were obtained and screened through TCMSP, and the PPI network of DCM-CF was constructed and then screened by CytoNCA plug-in. GO analysis and KEGG pathway enrichment analysis were carried out by Cluego plug-in. Combined with the results of network pharmacological analysis, cells in vitro were performed to verify the CF stimulated with high glucose or intervence with Yangxinshi, and the expressions of Cbl-b, p-smad2, and α-SMA were detected. Results. Yangxinshi might play a key role in reversing cardiac fibrosis in individuals with DCM by regulating the signal pathway of CBL and promoted the expression of Cbl-b and inhibited the expression of p-smad2 and α-SMA, verifying some predictive work via network pharmacology. Conclusion. Based on network pharmacology, this study demonstrates that the beneficial effect of Yangxinshi on CF is related to the Cbl-b/smad2 pathway, providing an idea for the therapeutic effect of Yangxinshi on cardiac fibrosis in DCM. | ||
| 653 | 0 | |a Other systems of medicine | |
| 700 | 0 | |a Kaiyi Wu |e verfasserin |4 aut | |
| 700 | 0 | |a Wenjing Li |e verfasserin |4 aut | |
| 700 | 0 | |a Xuguang Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Hao Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Zhiyi Jia |e verfasserin |4 aut | |
| 700 | 0 | |a Qingmei Han |e verfasserin |4 aut | |
| 700 | 0 | |a Xiaochen Tian |e verfasserin |4 aut | |
| 700 | 0 | |a Rong Sun |e verfasserin |4 aut | |
| 700 | 0 | |a Qinghua Lu |e verfasserin |4 aut | |
| 700 | 0 | |a Yusheng Liu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Evidence-Based Complementary and Alternative Medicine |d Hindawi Limited, 2004 |g (2022) |w (DE-627)DOAJ000122912 |x 1741427X |7 nnns |
| 773 | 1 | 8 | |g year:2022 |
| 856 | 4 | 0 | |u https://doi.org/10.1155/2022/3968494 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/87aff6f4dca747af80123bfe82779e13 |z kostenfrei |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1155/2022/3968494 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1741-4288 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 | ||